Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

1.7K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.7K
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

1.4K
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
1.4K
Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

2.3K
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
2.3K
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

667
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
667
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

1.2K
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
1.2K
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

1.7K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lipid profile with eslicarbazepine acetate and carbamazepine monotherapy in adult patients with newly diagnosed focal seizures: <i>post hoc</i> analysis of a phase III trial and open-label extension study.

Therapeutic advances in neurological disorders·2023
Same author

Prevalence of Subclinical Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease: Analysis of the Paracelsus 10,000 Cohort Study.

Medical principles and practice : international journal of the Kuwait University, Health Science Centre·2023
Same author

Network topology in brain tumor patients with and without structural epilepsy: a prospective MEG study.

Therapeutic advances in neurological disorders·2023
Same author

Acute symptomatic status epilepticus: Splitting or lumping? A proposal of classification based on real-world data.

Epilepsia·2023
Same author

How much refractory is 'refractory status epilepticus'? A retrospective study of treatment strategies and clinical outcomes.

Journal of neurology·2023
Same author

Relationships between education and non-alcoholic fatty liver disease.

European journal of internal medicine·2023

Related Experiment Video

Updated: Apr 5, 2026

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus
08:28

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus

Published on: April 5, 2011

18.3K

Pharmacotherapy for Status Epilepticus.

Eugen Trinka1, Julia Höfler, Markus Leitinger

  • 1Department of Neurology, Christian Doppler Klinik, Paracelsus Medical University Salzburg, Ignaz Harrerstrasse 79, 5020, Salzburg, Austria, e.trinka@salk.at.

Drugs
|August 28, 2015
PubMed
Summary
This summary is machine-generated.

Status epilepticus (SE) management lacks evidence for later stages. New trials are needed to guide treatment for established, refractory SE, with valproate and levetiracetam showing promise.

More Related Videos

Electrophoretic Delivery of &#947;-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

9.7K
Long-term Continuous EEG Monitoring in Small Rodent Models of Human Disease Using the Epoch Wireless Transmitter System
08:43

Long-term Continuous EEG Monitoring in Small Rodent Models of Human Disease Using the Epoch Wireless Transmitter System

Published on: July 21, 2015

26.5K

Related Experiment Videos

Last Updated: Apr 5, 2026

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus
08:28

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus

Published on: April 5, 2011

18.3K
Electrophoretic Delivery of &#947;-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

9.7K
Long-term Continuous EEG Monitoring in Small Rodent Models of Human Disease Using the Epoch Wireless Transmitter System
08:43

Long-term Continuous EEG Monitoring in Small Rodent Models of Human Disease Using the Epoch Wireless Transmitter System

Published on: July 21, 2015

26.5K

Area of Science:

  • Neurology
  • Pharmacology

Background:

  • Status epilepticus (SE) is a severe neurological emergency with high mortality.
  • Current pharmacotherapy for established, refractory, and super-refractory SE lacks robust evidence.
  • SE is clinically staged into early, established, refractory, and super-refractory phases.

Purpose of the Study:

  • To review the pharmacotherapy of status epilepticus (SE) based on a four-stage clinical approach.
  • To evaluate the efficacy and safety of antiepileptic drugs (AEDs) for SE based on scientific evidence.
  • To identify gaps in evidence and highlight the need for high-quality clinical trials.

Main Methods:

  • Comprehensive narrative review of SE pharmacotherapy.
  • Literature search using MEDLINE and reference tracking.
  • Analysis of AEDs based on pharmacological properties, efficacy, and safety data.

Main Results:

  • Intravenous lorazepam or intramuscular midazolam are effective for early SE (63-73% success).
  • Phenytoin or phenobarbital are common for established SE, despite safety concerns; valproate, levetiracetam, and lacosamide are alternatives.
  • Anesthetics are used for refractory/super-refractory SE, but evidence is limited.
  • Valproate and levetiracetam show promise as safer alternatives for established SE.

Conclusions:

  • Evidence for SE pharmacotherapy is limited, particularly for later stages.
  • Valproate and levetiracetam offer safe and effective options for established SE.
  • High-quality randomized controlled trials are crucial for guiding treatment decisions in established and refractory SE.